(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the finalization of a collaborative binding letter of intent (“LOI”) with ProMab Biotechnologies, Inc. (“ProMab”) to develop chimeric antigen receptor T-cell therapy (“CAR-T”) for hematological malignances and solid tumours.
The collaboration exploits Helix’s innovative single-domain antibody based CAR-T and ProMab’s proprietary vector designs, antibodies library and cell based production know-how. The immediate focus will involve preclinical work in support of a new investigational drug (“IND”) application of a CAR-T for hematological malignancies. Additional cell-based therapies will also be considered by mutual agreement of the parties. Such therapies may include combination of Helix’s newest DOS47 technology for alkalization of tumor microenvironment thus resulting in enhancement of cell-based immunotherapies.